Compare BHM & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHM | ELOX |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.4M | 41.0M |
| IPO Year | 2022 | N/A |
| Metric | BHM | ELOX |
|---|---|---|
| Price | $8.36 | $11.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 7.5K | ★ 51.3K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,734,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.88 | N/A |
| 52 Week Low | $8.05 | $10.00 |
| 52 Week High | $14.45 | $15.00 |
| Indicator | BHM | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 42.12 |
| Support Level | $8.05 | $10.51 |
| Resistance Level | $9.60 | $14.43 |
| Average True Range (ATR) | 0.28 | 1.76 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 0.00 | 29.03 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.